Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction

OBJECTIVE: It is unclear if activation of inflammatory pathways regulates proprotein convertase subtilisin-kexin type 9 (PCSK9) levels. APPROACH: We evaluated (1) the temporal course of serum PCSK9 during hospitalisation following acute coronary syndrome and associations with markers of inflammation...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueland, Thor, Kleveland, Ola, Michelsen, Annika E, Wiseth, Rune, Damås, Jan Kristian, Aukrust, Pål, Gullestad, Lars, Halvorsen, Bente, Yndestad, Arne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Coronary Artery Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150185/
https://www.ncbi.nlm.nih.gov/pubmed/30258647
http://dx.doi.org/10.1136/openhrt-2017-000765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150185/
https://www.ncbi.nlm.nih.gov/pubmed/30258647
http://dx.doi.org/10.1136/openhrt-2017-000765

Ejemplares similares